VEPEMB in elderly Hodgkin’s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study
Authors:
Open Access
- 1 January 2004
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 15 (1) , 123-128
Abstract
Background: In advanced age the prognosis of Hodgkin’s lymphoma (HL) is poor, but, as a consequence of the low incidence of HL in the elderly, prospective studies are lacking and the best treatment strategy is difficult to define. Patients and methods: One-hundred and five HL patients over 65 years of age were treated homogeneously with an original reduced-intensity regimen designed for HL in the elderly containing vinblastine, cyclophosphamide, procarbazine, etoposide, mitoxantrone and bleomycin (VEPEMB). Forty-eight early stage (IA–IIA) patients received three courses of VEPEMB followed by involved field irradiation. Fifty-seven advanced stage (IIB–IV) patients received six courses followed by radiotherapy limited to the areas of bulky disease. Results: Mean age was 71 years (range 66–83). Co-morbidities were present in 39 patients (37%). A treatment plan modification for poor tolerance or toxicity was needed in 18 patients. Results were satisfactory, even if they were better in early rather than in advanced stage disease: complete response rate 98% versus 58% (P P Conclusions: VEPEMB is an effective and low toxic regimen for HL in the elderly. Co-morbidity is a prognostic factor more important than age itself.Keywords
This publication has 22 references indexed in Scilit:
- Predictors of tolerance to chemotherapy in older cancer patientsEuropean Journal of Cancer, 2002
- Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Erythropoietin, Epoetin Beta, in Hematologic MalignanciesJournal of Clinical Oncology, 2002
- Is escalated BEACOPP a standard therapy for advanced Hodgkin's disease?The Hematology Journal, 2000
- Measuring comorbidity in older cancer patientsEuropean Journal of Cancer, 2000
- The comprehensive geriatric assessment: when, where, howCritical Reviews in Oncology/Hematology, 2000
- BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.Journal of Clinical Oncology, 1998
- What do we know on variables influencing clinical decision-making in elderly cancer patients?European Journal of Cancer, 1996
- Outcome of Hodgkin's disease in elderly patientsHematological Oncology, 1995
- Hodgkin's disease and age*European Journal of Haematology, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958